Researchers open 'Pandora's box' of potential cancer biomarkers

January 20, 2015 by Nicole Fawcett
Arul Chinnaiyan, M.D., Ph.D. Credit: University of Michigan Health System

A new analysis opens the door to discovery of thousands of potential new cancer biomarkers.

Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of a portion of the genome that has not been previously well-explored - long non-coding RNAs. This vast portion of the human genome has been considered the dark matter because so little is known about it. Emerging new evidence suggests that lncRNAs may play a role in cancer and that understanding them better could lead to new potential targets for improving , prognosis or treatment.

"We know about protein-coding genes, but that represents only 1-2 percent of the genome. Much less is known about the biology of the non-coding in terms of how it might function in a human disease like cancer," says senior study author Arul M. Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Professor of Pathology at the University of Michigan Medical School.

The researchers pulled together 25 independent datasets totaling 7,256 RNA sequencing samples. The data was from public sources such as The Cancer Genome Atlas project, as well as from the Michigan Center for Translational Pathology's archives. They applied high-throughput RNA sequencing technology to identify more than 58,000 lncRNA genes across normal tissue and a range of common cancer types.

Results of the study appear online in Nature Genetics.

"We used all of this data to decipher what the genomic landscape looks like in different tissues as well as in cancer," Chinnaiyan says. "This opens up a Pandora's box of all kinds of lncRNAs to investigate for biomarker potential."

The complete dataset, named the MiTranscriptome compendium, has been made available on a public website, http://www.mitranscriptome.org, for the scientific community to explore.

The researchers also identified one lncRNA, SChLAP1, as a potential biomarker for aggressive prostate cancer. SChLAP1 was more highly expressed in than in early stage disease. SChLAP1 was found primarily in , not in other cancers or normal cells, which gives researchers hope that a non-invasive test could be developed to detect SChLAP1. Such a test could be used to help patients and their doctors make treatment decisions for early stage .

"Some long non-coding RNAs tend to be exquisitely specific for , while protein-coding genes are often not. That's what makes lncRNAs a very promising target for developing biomarkers," Chinnaiyan says. "We hope that researchers will investigate the MiTransciptome compendium and begin to nominate lncRNAs for further study and development. It's likely that only a subset of these have true function but as a previously untapped area, it holds great promise."

Explore further: Team finds new genetic anomalies in lung cancer

More information: Nature Genetics, DOI: 10.1038/ng.3192 published online Jan. 19, 2015

Related Stories

Team finds new genetic anomalies in lung cancer

December 22, 2014
Developing effective treatments for lung cancer has been challenging, in part because so many genetic mutations play a role in the disease.

Researchers find ovarian cancer oncogene in 'junk DNA'

September 6, 2014
Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease.

Researchers find RNA molecules in urine and tissue that detect prostate cancer

October 10, 2014
Researchers at Sanford-Burnham Medical Research Institute have identified a set of RNA molecules that are detectable in tissue samples and urine of prostate cancer patients but not in normal healthy individuals. The study ...

What makes pancreatic cancer so aggressive? New study sheds light

January 15, 2015
New research from the University of Michigan Comprehensive Cancer Center helps explain why pancreatic cancer is so lethal, with fewer than a third of patients surviving even early stage disease.

Recommended for you

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

Blood test may help predict which breast cancers will recur

December 8, 2017
A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

Alcohol-abuse drug Antabuse kills cancer cells

December 8, 2017
A new study in Nature by an international team including researchers from Karolinska Institutet, reports that the alcohol-abuse drug Antabuse is effective against cancer. The study also identifies a potential mechanism of ...

2 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

antialias_physorg
5 / 5 (4) Jan 20, 2015
"This opens up a Pandora's box of all kinds of lncRNAs to investigate for biomarker potential."

I don't think "Pandora's box" means what he thinks it means (he might heave been looking for the word 'cornucopia')
JVK
1 / 5 (2) Jan 20, 2015
See also: http://genomebiol...5/12/537

"A considerable proportion of TEs in the exonic transcriptome lies in lncRNAs [24],[25]. The myriad lncRNAs implicated for critical roles in development [54]-[56] and disease [57],[58] emphasize the need for improved understanding of lncRNA function. A modular domain structure for lncRNAs has been hypothesized [59] but has, thus far, eluded a thorough characterization. Our observation that TE sequences contain functional RBP binding sites represents an important step towards characterizing TEs as one type of modular domain in lncRNAs where RBP-TE interactions may function."

This indicates others are beginning to understand the complexities of cell type differentiation. We will soon be rid of those who think in terms of mutations and evolution.

Excerpt 2) Through a variety of mechanisms acting on RNA, such as splicing, localization, and degradation, post-transcriptional regulation by RBPs also modulates protein abundance.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.